ES557315A0 - Procedimiento para la obtencion de peptidos - Google Patents

Procedimiento para la obtencion de peptidos

Info

Publication number: ES557315A0
Authority: ES; Spain
Prior art keywords: peptides; amides; contain; dna sequences; peptide
Prior art date: 1985-01-16
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

ES557315A

Other languages

English (en)

Other versions

ES8802161A1 (es

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Novartis AG

Original Assignee

Ciba Geigy AG

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1985-01-16

Filing date

1987-01-14

Publication date

1988-04-01

1987-01-14 Application filed by Ciba Geigy AG filed Critical Ciba Geigy AG

1988-04-01 Publication of ES8802161A1 publication Critical patent/ES8802161A1/es

1988-04-01 Publication of ES557315A0 publication Critical patent/ES557315A0/es

Status Expired legal-status Critical Current

Links

108090000765 processed proteins & peptides Proteins 0.000 title abstract 5
102000004196 processed proteins & peptides Human genes 0.000 title abstract 4
238000000034 method Methods 0.000 title abstract 2
108091028043 Nucleic acid sequence Proteins 0.000 abstract 2
208000018083 Bone metabolism disease Diseases 0.000 abstract 1
125000003275 alpha amino acid group Chemical group 0.000 abstract 1
150000001408 amides Chemical class 0.000 abstract 1
125000003277 amino group Chemical group 0.000 abstract 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
208000035475 disorder Diseases 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1
244000005700 microbiome Species 0.000 abstract 1
239000000825 pharmaceutical preparation Substances 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57527—Calcitonin gene related peptide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/26—Containing cys-cys disulfide bridge between nonadjacent cysteine residues

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Genetics & Genomics (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Biophysics (AREA)
Toxicology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Endocrinology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Obesity (AREA)
Hematology (AREA)
Hospice & Palliative Care (AREA)
Diabetes (AREA)
Neurosurgery (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Investigating Or Analysing Biological Materials (AREA)

ES557315A 1985-01-16 1987-01-14 Procedimiento para la obtencion de peptidos Expired ES8802161A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CH18885		1985-01-16

Publications (2)

Publication Number	Publication Date
ES8802161A1 ES8802161A1 (es)	1988-04-01
ES557315A0 true ES557315A0 (es)	1988-04-01

Family

ID=4181264

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
ES550911A Expired ES8707974A1 (es)	1985-01-16	1986-01-15	Procedimiento para la obtencion de un peptido
ES557315A Expired ES8802161A1 (es)	1985-01-16	1987-01-14	Procedimiento para la obtencion de peptidos

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
ES550911A Expired ES8707974A1 (es)	1985-01-16	1986-01-15	Procedimiento para la obtencion de un peptido

Country Status (12)

Country	Link
US (1)	US4720483A (es)
EP (1)	EP0188400B1 (es)
JP (1)	JPH0780908B2 (es)
AT (1)	ATE78040T1 (es)
CA (1)	CA1339365C (es)
DE (1)	DE3685885D1 (es)
DK (1)	DK17986A (es)
ES (2)	ES8707974A1 (es)
FI (1)	FI86547C (es)
GR (1)	GR860081B (es)
IE (1)	IE58190B1 (es)
PT (1)	PT81837B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5221518A (en) *	1984-12-14	1993-06-22	Mills Randell L	DNA sequencing apparatus
GB8720115D0 (en) *	1987-08-26	1987-09-30	Cooper G J S	Treatment of diabetes mellitus
DE3888357T2 (de) *	1987-06-22	1994-09-15	Merck & Co Inc	Cyclosporin-Derivate, die eine modifizierte Aminosäure auf Stellung 8 tragen.
US5266561A (en) *	1988-01-11	1993-11-30	Amylin Pharmaceuticals, Inc.	Treatment of type 2 diabetes mellitus
AU629552B2 (en) *	1988-06-16	1992-10-08	Teijin Limited	S-sulfonated calcitonin derivatives
US5175145A (en) *	1988-08-26	1992-12-29	Amylin Pharmaceuticals, Inc.	Treatment of diabetes mellitus with amylin agonists
GB8829432D0 (en) *	1988-12-15	1989-02-01	Celltech Ltd	Enzymatic process
EP0448513A3 (en) *	1990-03-21	1991-12-27	Japat Ltd	Process for production of peptidylglycine alpha-hydroxylating monooxygenase and use thereof
DE69227517D1 (de) *	1991-08-08	1998-12-10	Amylin Pharmaceuticals Inc	Produktion von peptid-amiden
US5569604A (en) *	1993-09-03	1996-10-29	The University Of Iowa Research Foundation	Calcitonin/calcitonin gene related peptide enhancer element and associated DNA binding proteins
US20080119427A1 (en) *	1996-06-06	2008-05-22	Isis Pharmaceuticals, Inc.	Double Strand Compositions Comprising Differentially Modified Strands for Use in Gene Modulation
US20050119470A1 (en) *	1996-06-06	2005-06-02	Muthiah Manoharan	Conjugated oligomeric compounds and their use in gene modulation
US20040171031A1 (en) *	1996-06-06	2004-09-02	Baker Brenda F.	Sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
US20050042647A1 (en) *	1996-06-06	2005-02-24	Baker Brenda F.	Phosphorous-linked oligomeric compounds and their use in gene modulation
US20040147022A1 (en) *	1996-06-06	2004-07-29	Baker Brenda F.	2'-methoxy substituted oligomeric compounds and compositions for use in gene modulations
US7812149B2 (en) *	1996-06-06	2010-10-12	Isis Pharmaceuticals, Inc.	2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
US20040203024A1 (en) *	1996-06-06	2004-10-14	Baker Brenda F.	Modified oligonucleotides for use in RNA interference
US20050053976A1 (en) *	1996-06-06	2005-03-10	Baker Brenda F.	Chimeric oligomeric compounds and their use in gene modulation
US5898031A (en) *	1996-06-06	1999-04-27	Isis Pharmaceuticals, Inc.	Oligoribonucleotides for cleaving RNA
US9096636B2 (en) *	1996-06-06	2015-08-04	Isis Pharmaceuticals, Inc.	Chimeric oligomeric compounds and their use in gene modulation
AU725954B2 (en) *	1996-08-15	2000-10-26	Board Of Trustees Of Southern Illinois University, The	Enhancement of antimicrobial peptide activity by metal ions
DE19652033A1 (de) *	1996-12-13	1998-06-18	Irmgard Dr Med Guertner	Neuropeptid (CGRP) als Modulator zur Zelldifferenzierung und Proliferation
WO2004043979A2 (en) *	2002-11-05	2004-05-27	Isis Pharmaceuticals, Inc.	Sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
US20060241072A1 (en) *	2003-06-20	2006-10-26	Isis Pharmaceuticals, Inc.	Oligomeric compounds for use in gene modulation
WO2005070444A2 (en) *	2004-01-13	2005-08-04	Vasogenix Pharmaceuticals, Inc.	Methods for treating acute myocardial infarction by calcitonin gene related peptide and compositions containing the same
EP1703895A2 (en) *	2004-01-13	2006-09-27	Vasogenix Pharmaceuticals, Inc.	Controlled release cgrp delivery composition for cardiovascular and renal indications
CA2552758A1 (en)	2004-01-13	2005-08-04	Vasogenix Pharmaceuticals, Inc.	Methods for treating acute myocardial infarction by administering calcitonin gene related peptide and compositions containing the same
US8569474B2 (en) *	2004-03-09	2013-10-29	Isis Pharmaceuticals, Inc.	Double stranded constructs comprising one or more short strands hybridized to a longer strand
US8394947B2 (en) *	2004-06-03	2013-03-12	Isis Pharmaceuticals, Inc.	Positionally modified siRNA constructs
US7884086B2 (en) *	2004-09-08	2011-02-08	Isis Pharmaceuticals, Inc.	Conjugates for use in hepatocyte free uptake assays
US8168592B2 (en) *	2005-10-21	2012-05-01	Amgen Inc.	CGRP peptide antagonists and conjugates
JP4884193B2 (ja) *	2006-12-15	2012-02-29	ヤマハ発動機株式会社	船舶
WO2011051312A1 (en)	2009-10-30	2011-05-05	Novo Nordisk A/S	Derivatives of cgrp
WO2013028783A1 (en) *	2011-08-22	2013-02-28	Suganit Systems, Inc.	Production of bio-butanol and related products
WO2025196125A1 (en) *	2024-03-19	2025-09-25	Epoqe Pharma Aps	N-terminally modified calcitonin gene-related peptide analogues

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5374618A (en) *	1983-06-15	1994-12-20	Celltech Limited	Calcitonin peptides, and gene related pharmaceutical compositions
US4530838A (en) *	1983-07-08	1985-07-23	The Salk Institute For Biological Studies	Synthetic calcitonin-gene-related peptides for lowering blood pressure or gastric acid secretion in mammals
GB8327346D0 (en) *	1983-10-12	1983-11-16	Morris H R	Peptide
US4549986A (en) *	1983-12-23	1985-10-29	The Salk Institute For Biological Studies	Human CGRP

1986
- 1986-01-10 DE DE8686810007T patent/DE3685885D1/de not_active Expired - Lifetime
- 1986-01-10 AT AT86810007T patent/ATE78040T1/de not_active IP Right Cessation
- 1986-01-10 EP EP86810007A patent/EP0188400B1/de not_active Expired - Lifetime
- 1986-01-13 FI FI860153A patent/FI86547C/fi not_active IP Right Cessation
- 1986-01-14 JP JP61006159A patent/JPH0780908B2/ja not_active Expired - Lifetime
- 1986-01-14 GR GR860081A patent/GR860081B/el unknown
- 1986-01-14 CA CA000499545A patent/CA1339365C/en not_active Expired - Lifetime
- 1986-01-14 PT PT81837A patent/PT81837B/pt not_active IP Right Cessation
- 1986-01-15 DK DK17986A patent/DK17986A/da not_active Application Discontinuation
- 1986-01-15 ES ES550911A patent/ES8707974A1/es not_active Expired
- 1986-01-15 IE IE11686A patent/IE58190B1/en not_active IP Right Cessation
- 1986-01-15 US US06/819,168 patent/US4720483A/en not_active Expired - Lifetime
1987
- 1987-01-14 ES ES557315A patent/ES8802161A1/es not_active Expired

Also Published As

Publication number	Publication date
DK17986D0 (da)	1986-01-15
EP0188400A2 (de)	1986-07-23
ES550911A0 (es)	1987-09-01
US4720483A (en)	1988-01-19
FI860153A0 (fi)	1986-01-13
FI86547B (fi)	1992-05-29
DE3685885D1 (de)	1992-08-13
ES8802161A1 (es)	1988-04-01
FI86547C (fi)	1992-09-10
JPH0780908B2 (ja)	1995-08-30
DK17986A (da)	1986-07-17
EP0188400B1 (de)	1992-07-08
CA1339365C (en)	1997-08-26
ATE78040T1 (de)	1992-07-15
JPS61172899A (ja)	1986-08-04
ES8707974A1 (es)	1987-09-01
IE860116L (en)	1986-07-16
PT81837B (pt)	1988-05-27
IE58190B1 (en)	1993-07-28
PT81837A (en)	1986-02-01
FI860153L (fi)	1986-07-17
GR860081B (en)	1986-04-29
EP0188400A3 (en)	1988-08-31

Legal Events

Date	Code	Title	Description
1999-12-16	FD1A	Patent lapsed	Effective date: 19991007

Publication	Publication Date	Title
ES550911A0 (es)	1987-09-01	Procedimiento para la obtencion de un peptido
ATE363535T1 (de)	2007-06-15	Stabile bakterizide proteine, welche die permeabilität erhöhen und pharmazeutische zusammensetzungen, diese enthaltend
DK382786D0 (da)	1986-08-11	Overfladeaktivt rekombinant-alveolarprotein
HUP0004560A2 (hu)	2001-04-28	Törést gyógyító PTHrP analógok
ATE108662T1 (de)	1994-08-15	Antimikrobielle peptide, zusammensetzungen, die diese enthalten, und verwendungen daraus.
ATE213499T1 (de)	2002-03-15	Peptidanaloge des menschlichen, basischen myelinproteins mit substitution an position 91 zur behandlung der multiplen sklerose
ATE174932T1 (de)	1999-01-15	Modifizierte vip-derivate und sie enthaltende pharmazeutische zusammensetzungen
DK595187A (da)	1988-07-21	Minactivin og fremgangsmaade til fremstilling deraf
DK0422215T3 (da)	1999-05-25	Antibakterielle peptider og antimalariapeptider
DE60234843D1 (de)	2010-02-04	Modifizierte peptide und deren verwendung zur behandlung von autoimmunkrankheiten
KR920700224A (ko)	1992-02-19	신규의 생리활성 펩티드 및 이를 유효성분으로서 함유한 칼슘대사 조절제
DK625889A (da)	1990-06-14	Serinprotease-inhibitor-proteiner, laegemidler indeholdende disse, dna-sekvenser, som koder for disse proteiner, og fremgangsmaader til fremstilling af disse proteiner, laegemidler og dna-sekvenser